House of Commons - Committee of Public Accounts: Access to Clinical Trial Information and the Stockpiling of Tamiflu - HC 295 PDF Download

Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download House of Commons - Committee of Public Accounts: Access to Clinical Trial Information and the Stockpiling of Tamiflu - HC 295 PDF full book. Access full book title House of Commons - Committee of Public Accounts: Access to Clinical Trial Information and the Stockpiling of Tamiflu - HC 295 by Great Britain: Parliament: House of Commons: Committee of Public Accounts. Download full books in PDF and EPUB format.

House of Commons - Committee of Public Accounts: Access to Clinical Trial Information and the Stockpiling of Tamiflu - HC 295

House of Commons - Committee of Public Accounts: Access to Clinical Trial Information and the Stockpiling of Tamiflu - HC 295 PDF Author: Great Britain: Parliament: House of Commons: Committee of Public Accounts
Publisher: The Stationery Office
ISBN: 9780215065971
Category : Business & Economics
Languages : en
Pages : 52

Book Description
The report Access To Clinical Trial Information And The Stockpiling Of Tamiflu (HC 295) examines two separate but connected issues; the routine withholding of clinical trial information from doctors and researchers, and the effectiveness of stockpiling of Tamiflu during an influenza pandemic. The full results of clinical trials are being routinely and legally withheld from doctors and researchers by the manufacturers of medicines. The ability of doctors, researchers and patients to make informed decisions about treatments is being undermined. Regulators and the industry have recently made proposals to open up access, but these do not cover the issue of access to the results of trials in the past which bear on the efficacy and safety of medicines in use today. Research suggests that the probability of completed trials being published is roughly 50%. Trials which give a favorable verdict are about twice as likely to be published as trials giving unfavorable